Satori Pharmaceuticals

  • Home
  • About Us
    • Overview
    • Leadership
    • Scientific and Clinical Advisors
    • Board of Directors
    • Investors
    • Contact
  • The Science of AD
    • Pathogenesis of AD
    • Amyloid Hypothesis
    • Gamma Sectretase Modulation
    • FAQs About AD
    • Resources
  • Research and Development
    • Origins of GSM Program
    • SPI-1865
    • Pre-Clinical Development
    • GSM FAQs
  • News and Events
    • Press Releases
    • Publications and Presentations
    • Satori Press Coverage
    • Events

About Us

Intent on slowing or stopping the progression of Alzheimer’s disease

Satori Pharmaceuticals is developing life-changing therapeutics for Alzheimer's disease (AD). The Company is led by a seasoned management team with deep CNS drug discovery and development experience. Combined, the team has helped develop over 100 clinical candidates and more than 10 approved drugs. This substantial experience bringing novel medicines to patients enables the management team to employ a top of industry approach to the development of its drug candidates – utilizing clinical strategies that are familiar to pharmaceutical companies working in AD.

The internal team is supported by a world-class team of scientific advisors, made up of many of the industry's leading experts on AD, an experienced Board of Directors with a range of industry backgrounds and a stellar group of life science investors with a long track record of nurturing important new medicines to the market.

Read More

News and Events   View All

July 18, 2012

Data Underscore Promise of Satori Pharmaceuticals' Gamma-Secretase Modulator Program in Treatment of Alzheimer's Disease

 

July 10, 2012

Satori Pharmaceuticals to Present Data Highlighting Promise of Gamma-Secretase Modulators in Treatment of Alzheimer's Disease

 

February 23, 2012

Satori Pharmaceuticals Raises $15M in New Funding; Donald Hayden Elected Chairman of the Board of Directors; David Schnell and Stephen Muniz Become Members

 

July 18, 2011

Satori Pharmaceuticals Demonstrates its Approach to Modulating Gamma-Secretase Effective In Reducing Plaque-Forming Amyloid Beta Peptide

 

Satori Pharmaceuticals © 2012    Sitemap    Contact